electroCore Reports Record Q3 Sales, Lowers 2026 Revenue Guidance
Third-quarter net sales were a record $9.7 million. GAAP net loss improved by $2.0 million to $1.3 million, and Adjusted EBITDA loss narrowed to $0.7 million. electroCore lowered its 2026 revenue outlook to $39 million-$42 million, saying expected growth acceleration has shifted to 2027.
The company reported record net sales of $9.7 million for the third quarter ended September 30, 2026, driven by growth in U.S. prescription sales, particularly within the U.S. Department of Veterans Affairs. GAAP net loss improved by $2.0 million to $1.3 million, while Adjusted EBITDA loss narrowed to $0.7 million.
Management lowered its full-year 2026 revenue guidance to a range of $39 million to $42 million, noting that expected growth acceleration has shifted to 2027. The company also highlighted a 510(k) submission for a new indication for its Quell device to treat chronic chemotherapy-induced peripheral neuropathy.